Menu
You have to log in or sign up before you can proceed.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

 
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical

Quantum Genomics to receive up to $50 million in upfront and milestone payments plus double-digit royalties on sales

Qilu Pharmaceutical to receive an exclusive license to develop and commercialize

IMV Inc. Re-establishes At-the-Market Facility: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. Re-establishes At-the-Market Facility


IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated October 16

Medigene AG: Drei Poster Präsentationen von Medigene auf dem SITC Annual Meeting
Medigene AG: Drei Poster Präsentationen von Medigene auf dem SITC Annual Meeting

 

Planegg/Martinsried (15.10.2020) - Wissenschaftler der Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit klinischen Projekten fokussiert auf die

Medigene AG: Three Medigene poster presentations at SITC Annual Meeting
Medigene AG: Three Medigene poster presentations at SITC Annual Meeting

 

Planegg/Martinsried (15.10.2020) - Scientists of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell

Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming SITC Annual Meeting: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming SITC Annual Meeting


IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that

 
BOIRON : Projected timetable of the next publications and events 2021
BOIRON : Projected timetable of the next publications and events 2021

The projected timetable of the next publications and events for the year 2021 is the following one:

Publications Date of publication (after market closing) Information meetings
Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB

EnWave unterzeichnet Technologiebewertungsabkommen inklusive Lizenzoptionen mit amerikanischem Industriehanfproduzenten
EnWave unterzeichnet Technologiebewertungsabkommen inklusive Lizenzoptionen mit amerikanischem Industriehanfproduzenten

Vancouver, B.C., 14. Oktober 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab

EnWave Signs Technology Evaluation and License Option Agreement with American Industrial Hemp Producer
EnWave Signs Technology Evaluation and License Option Agreement with American Industrial Hemp Producer

Vancouver, B.C., October 14, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today

Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com
Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis (LN) disease-state awareness campaign for

Formycon: Sensationelle News!
Formycon: Sensationelle News!

Wie der Biosimilar-Spezialist Formycon (WKN: A1EWVY) heute früh vermeldete, erhält man Fördermittel in Höhe von 290.000 Euro für das Projekt "Charakterisierung von ACE2-IgG-Konstrukten", einem

NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA


Regulatory News:



NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today

Selecta Biosciences: NBC sagt Byebye nach +60% in einer Woche
Selecta Biosciences: NBC sagt Byebye nach +60% in einer Woche

Zu Monatsbeginn konnten Mitglieder des No Brainer Clubs mit der Aktie von Selecta Biosciences (WKN: A2AML0) ein weiteres Schnäppchen ergattern. Nach vermeintlich enttäuschenden Studiendaten rutschte

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

IMV Provides Updates On COVID-19 Vaccine Program: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Provides Updates On COVID-19 Vaccine Program


IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today provides updates on

CO.DON AG: Erfolgreicher Abschluss der Kapitalerhöhung
CO.DON AG: Erfolgreicher Abschluss der Kapitalerhöhung

-          vollständige Platzierung aller angebotenen Aktien

-          Bruttoemissionserlös in Höhe von rund 1,5 Mio. EUR

 

Berlin / Teltow / Leipzig, 08. Oktober 2020 – Die CO.DON AG (ISIN

Santhera: Endgültiger Studienstopp von DMD-Medikament
Santhera: Endgültiger Studienstopp von DMD-Medikament

Dämpfer für Santhera Pharmaceuticals (WKN: A0LCUK): Die Schweizer Biotechschmiede stellt die zulassungsrelevante Phase-3-Studie mit Puldysa bei Patienten mit Duchenne-Muskeldystrophie (DMD) ein. Die

Medigene AG: Medigene weitet Patentschutz ihrer Technologien aus
Medigene AG: Medigene weitet Patentschutz ihrer Technologien aus

Planegg/Martinsried (06.10.2020) - Der Medigene AG (Medigene, FWB: MDG1, Prime Standard), einem Immunonkologie-Unternehmen mit klinischen Projekten fokussiert auf die Entwicklung

Medigene AG: Medigene expands patent protection of its technologies
Medigene AG: Medigene expands patent protection of its technologies

 

Planegg/Martinsried (06.10.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader

Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today

EnWave unterzeichnet Geräte-Kaufvertrag mit Intakt Snacks aus Chile
EnWave unterzeichnet Geräte-Kaufvertrag mit Intakt Snacks aus Chile

Vancouver, B.C., 29. September 2020, EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" -

EnWave Signs Equipment Purchase Agreement with Intakt Snacks of Chile
EnWave Signs Equipment Purchase Agreement with Intakt Snacks of Chile

Vancouver, B.C., September 29, 2020, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/play/enwave-update-on-covid-19-impact-rev-machine-sale